BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 34378540)

  • 21. Design, synthesis and anti-hepatocellular carcinoma activity of 3-arylisoquinoline alkaloids.
    Deng X; Luo T; Li Z; Wen H; Zhang H; Yang X; Lei F; Liu D; Shi T; Zhao Q; Wang Z
    Eur J Med Chem; 2022 Jan; 228():113985. PubMed ID: 34802836
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Synthesis and biological evaluation of phenyl substituted polyoxygenated xanthone derivatives as anti-hepatoma agents.
    Dai M; Yuan X; Kang J; Zhu ZJ; Yue RC; Yuan H; Chen BY; Zhang WD; Liu RH; Sun QY
    Eur J Med Chem; 2013 Nov; 69():159-66. PubMed ID: 24013415
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Design, synthesis and biological evaluation of novel 1,3,4-trisubstituted pyrazole derivatives as potential chemotherapeutic agents for hepatocellular carcinoma.
    Harras MF; Sabour R
    Bioorg Chem; 2018 Aug; 78():149-157. PubMed ID: 29567429
    [TBL] [Abstract][Full Text] [Related]  

  • 24.
    Keshari AK; Singh AK; Raj V; Rai A; Trivedi P; Ghosh B; Kumar U; Rawat A; Kumar D; Saha S
    Drug Des Devel Ther; 2017; 11():1623-1642. PubMed ID: 28615927
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Water-soluble derivatives of evodiamine: Discovery of evodiamine-10-phosphate as an orally active antitumor lead compound.
    Chen S; Bi K; Wu S; Li Y; Huang Y; Sheng C; Dong G
    Eur J Med Chem; 2021 Aug; 220():113544. PubMed ID: 34052678
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The Antitumor Effects of Britanin on Hepatocellular Carcinoma Cells and its Real-Time Evaluation by In Vivo Bioluminescence Imaging.
    Li H; Du G; Yang L; Pang L; Zhan Y
    Anticancer Agents Med Chem; 2020; 20(9):1147-1156. PubMed ID: 32106805
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Design, synthesis and biological evaluation of new pyrrolidine carboxamide analogues as potential chemotherapeutic agents for hepatocellular carcinoma.
    Omar HA; Zaher DM; Srinivasulu V; Hersi F; Tarazi H; Al-Tel TH
    Eur J Med Chem; 2017 Oct; 139():804-814. PubMed ID: 28865276
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Design and synthesis of parthenolide and 5-fluorouracil conjugates as potential anticancer agents against drug resistant hepatocellular carcinoma.
    Ding Y; Li S; Ge W; Liu Z; Zhang X; Wang M; Chen T; Chen Y; Zhang Q
    Eur J Med Chem; 2019 Dec; 183():111706. PubMed ID: 31553932
    [TBL] [Abstract][Full Text] [Related]  

  • 29. 9-bis[2-(pyrrolidin-1-yl)ethoxy]-6-{4-[2-(pyrrolidin-1-yl)ethoxy]phenyl}-11H-indeno[1, 2-c]quinolin-11-one (BPIQ), A Quinoline Derivative Inhibits Human Hepatocellular Carcinoma Cells by Inducing ER Stress and Apoptosis.
    Chang WT; Fong Y; Chuang SC; Chou CK; Chou HL; Yang CF; Tseng CH; Chen YL; Chiu CC
    Anticancer Agents Med Chem; 2017; 17(5):692-700. PubMed ID: 27491935
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A polymeric prodrug of cisplatin based on pullulan for the targeted therapy against hepatocellular carcinoma.
    Wang Y; Liu Y; Liu Y; Zhou W; Wang H; Wan G; Sun D; Zhang N; Wang Y
    Int J Pharm; 2015 Apr; 483(1-2):89-100. PubMed ID: 25681730
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Growth inhibitor of human hepatic carcinoma HepG2 cells by evodiamine is associated with downregulation of PRAME.
    Zhu H; Ge K; Lu J; Jia C
    Naunyn Schmiedebergs Arch Pharmacol; 2019 Dec; 392(12):1551-1560. PubMed ID: 31359090
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Synthetic strigolactone analogues reveal anti-cancer activities on hepatocellular carcinoma cells.
    Hasan MN; Choudhry H; Razvi SS; Moselhy SS; Kumosani TA; Zamzami MA; Omran Z; Halwani MA; Al-Babili S; Abualnaja KO; Al-Malki AL; Alhosin M; Asami T
    Bioorg Med Chem Lett; 2018 Apr; 28(6):1077-1083. PubMed ID: 29456109
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A naphthalimide-polyamine conjugate preferentially accumulates in hepatic carcinoma metastases as a lysosome-targeted antimetastatic agent.
    Ma J; Li L; Yue K; Zhang Z; Su S; Chen Y; Yu L; Zhang P; Ma R; Li Y; Ma Y; Jia H; Wang C; Wang J; Xie S
    Eur J Med Chem; 2021 Oct; 221():113469. PubMed ID: 33965862
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Hepatocellular Carcinoma Targeting and Pharmacodynamics of Paclitaxel Nanoliposomes Modified by Glycyrrhetinic Acid and Ferric Tetroxide.
    Zhao L; Liang L; Guo M; Li M; Yu X; Wang Y; Wang Y
    Curr Top Med Chem; 2021 Oct; 21(14):1268-1284. PubMed ID: 34620053
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Structural simplification of evodiamine: Discovery of novel tetrahydro-β-carboline derivatives as potent antitumor agents.
    Ma Z; Huang Y; Wan K; Zhu F; Sheng C; Chen S; Liu D; Dong G
    Bioorg Med Chem Lett; 2021 May; 40():127954. PubMed ID: 33744440
    [TBL] [Abstract][Full Text] [Related]  

  • 36. MEK inhibition by cobimetinib suppresses hepatocellular carcinoma and angiogenesis in vitro and in vivo.
    Tong X; Wang Q; Wu D; Bao L; Yin T; Chen H
    Biochem Biophys Res Commun; 2020 Feb; 523(1):147-152. PubMed ID: 31836141
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A Critical YAP in Malignancy of HCC Is Regulated by Evodiamine.
    Yun UJ; Bae SJ; Song YR; Kim YW
    Int J Mol Sci; 2022 Feb; 23(3):. PubMed ID: 35163776
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Design, synthesis, and biological evaluation of indazole derivatives as selective and potent FGFR4 inhibitors for the treatment of FGF19-driven hepatocellular cancer.
    Chen X; Liu Y; Zhang L; Chen D; Dong Z; Zhao C; Liu Z; Xia Q; Wu J; Chen Y; Zheng X; Cai Y
    Eur J Med Chem; 2021 Mar; 214():113219. PubMed ID: 33618175
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Design, synthesis and bioactivity evaluation of favorable evodiamine derivative scaffold for developing cancer therapy.
    Liang Z; Wang Y; Zhang H; Deng J; Lei F; Li J; Shi T; Wang S; Li R; Wang Z
    Eur J Med Chem; 2022 Sep; 239():114530. PubMed ID: 35728506
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Synthesis, in vitro and in vivo evaluation of novel substituted N-(4-(2-(4-benzylpiperazin-1-yl)ethoxy)phenyl)-N-methyl-quinazolin-4-amines as potent antitumor agents.
    Cao D; Wang X; Lei L; Ma L; Wang F; Wang C; Tang M; Xiang W; Wang T; Li H; Chen L
    Bioorg Med Chem Lett; 2016 Apr; 26(8):1931-5. PubMed ID: 26979159
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.